Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Respiratory Distress Syndrome
- COVID-19
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Primary Aim: • To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: To determine efficacy of SGB in slowing the progression of ARDS
Primary Aim: • To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: To determine efficacy of SGB in slowing the progression of ARDS
Tracking Information
- NCT #
- NCT04402840
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ali R Rezai, MD West Virginia University
Get Well Soon